We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
RubrYc Therapeutics is a discovery-stage therapeutic antibody business focused on addressing unmet needs in Oncology and Autoimmune Diseases. The Company was founded in 2017 and launched in April, 2018 with a $10M Series A Preferred financing. RubrYc has developed the Interface Discovery Engine – the operating system the Company employs, leveraging machine learning to realize critical efficiency gains in drug discovery. Team RubrYc maintains intense focus on advancing its proprietary pipeline programs, while engaging in target-specific Platform Partnerships with industry incumbents. The Company will complete platform feasibility, demonstrate non-GLP PoC with its molecules, and raise Series B in 2019.